Clinical Trials Directory

Trials / Completed

CompletedNCT04252833

Open-label, Crossover, Food Effect Study to Evaluate CT-044 in Healthy Human Volunteers

Open-label, Crossover, Food Effect Study to Evaluate the Single Dose Pharmacokinetics of CT-044, a Reactive Species Decomposition Accelerant, in Healthy Human Volunteers

Status
Completed
Phase
Phase 1
Study type
Interventional
Enrollment
10 (actual)
Sponsor
Lotus Clinical Research, LLC · Academic / Other
Sex
All
Age
18 Years – 55 Years
Healthy volunteers
Accepted

Summary

This open-label study will be conducted to assess the bioavailability and PK of oral single doses of CT-044 following administration with and without food and to evaluate the safety and tolerability of CT-044 when given with and without food.

Detailed description

The food effect study will be an open-label, 2-sequence, balanced crossover design in 12 subjects previously untreated with CT-044. Eligible subjects will be admitted to the Clinical Trial Unit on the day prior to dosing and remain in house until Day 3. Each subject will receive CT-044 single oral dose once under fed conditions (i.e., a high fat meal per FDA recommendations) and once in the fasted state. 9 Subjects will return to the Clinical Trial Unit on an outpatient basis for follow-up. Subjects will return to the Clinical Trial Unit to be treated by the second sequence after a washout period of at least 7 days, but no more than 14 days. All procedures will be repeated for the second treatment sequence. When possible, the procedures conducted at the 144-hour follow-up visit for the first sequence may serve as baseline for the second sequence of the crossover.

Conditions

Interventions

TypeNameDescription
DRUGCT-044CT-044 HCl is a reactive species decomposition accelerant

Timeline

Start date
2020-02-18
Primary completion
2020-03-16
Completion
2020-03-16
First posted
2020-02-05
Last updated
2020-06-12

Locations

1 site across 1 country: United States

Regulatory

Source: ClinicalTrials.gov record NCT04252833. Inclusion in this directory is not an endorsement.